If you’re reading this, you’re probably not someone who needs to be convinced that digital pathology exists. You know it exists. You’ve heard the pitch. You’ve sat through the conference presentations. You may have even watched a colleague’s implementation go sideways.
The question you’re actually asking is more specific: is it worth the disruption? Is it better for me, for my practice, for my patients? Or is this mostly a technology industry looking for buyers?
That’s a fair question. And it deserves a more honest answer than most digital pathology content provides.
First: Your Skepticism Is Reasonable
Pathologists are trained to evaluate evidence carefully before drawing conclusions. Applying that same standard to a major workflow change is not resistance; it’s good judgment.
Dr. Liron Pantanowitz, Chair of Pathology at UPMC and past president of the Digital Pathology Association, has studied this question closely. He believes the mindset of pathologists is now the primary barrier to digital adoption, with the technical and regulatory obstacles having been largely resolved. “When you actually talk to them one-on-one and you explain to them,” he noted on PathPulse, “and I often bring this conversation to a real-world experience — everything in their world outside of work is digital. Everything at work is not digital.” The disconnect between how pathologists live and how they work is a useful frame for understanding why the hesitation persists even as the technology matures.
The concerns that come up most often are legitimate:
“My current system works.” It does. Traditional microscopy has served pathology for over a century. The diagnostic quality of an experienced pathologist working with a well-prepared glass slide is not in question. The case for digital pathology isn’t that glass slides are bad. It’s that the logistics around glass slides create unnecessary constraints on what you can do, where you can do it, and who you can work with.
“I’ve seen implementations fail.” So have we. The implementations that fail most often do so because of poor workflow design, inadequate infrastructure, or rushed go-lives without sufficient change management. Not because the technology itself doesn’t work. Dr. Syed Hoda, Director of Digital Pathology at NYU Langone, described institutions that had digital pathology running “like a hobby” for years: one scanner in a room, used occasionally for education, never set up for actual clinical workflow.
“I’ll lose something I’m good at.” This one is real and worth taking seriously. Pathologists who have spent decades optimizing their glass slide workflow have genuine expertise in that workflow. Transition involves a learning curve. The question is whether what you gain on the other side is worth the friction of getting there. Most pathologists who have made the transition say yes, but that answer deserves specifics.
“It’ll slow me down.” This is probably the most common practical objection, and it deserves a direct answer. Yes, there is a learning curve. And yes, during the transition period, throughput will likely dip temporarily. What the evidence shows, however, is that this is a short-term cost with a long-term payoff. Once the new workflow becomes habitual, the time savings from instant case distribution, no slide sorting, faster consultation, reduced to no commuting time, and AI-assisted triage compound. The pathologists who report the greatest efficiency gains from digital pathology are overwhelmingly the ones who were initially the most skeptical about it. The key is choosing a platform with rendering speed fast enough that loading time never becomes a bottleneck. Lag is the single most common adoption killer, and it’s a product selection problem.
“I’m worried about being replaced.” This concern shows up more often in private conversations than in conference Q&As, which means it’s worth addressing openly. AI tools in digital pathology are diagnostic aids, not replacements. They assist with specific, well-defined tasks: flagging regions of interest, counting cells, quantifying biomarkers, pre-screening high-volume cases. The interpretive diagnosis, the judgment that determines what a finding means for a patient, remains the pathologist’s domain and is likely to remain so for the foreseeable future. What digital pathology and AI actually do is make pathologists more productive and more capable, not redundant. The practices that are thriving in this environment aren’t the ones that resisted the technology; they’re the ones that adopted it and expanded their scope of practice as a result. Dr. Hoda’s experience at NYU Langone is illustrative: going fully digital didn’t diminish pathology’s role in the institution. It elevated it.
“I just don’t think it’ll be worth it.” This is the most honest version of the skepticism, and it’s worth taking at face value. The ROI case for digital pathology depends heavily on your specific situation: your case volume, your current workflow friction points, your geography, your staffing model, and your growth plans. For a solo pathologist in a well-functioning single-site practice with no remote coverage needs, the case is genuinely different than for a multi-site group struggling with consultation turnaround times and slide logistics. The honest answer is that digital pathology is not universally worth it for every practice in every context right now. What is worth doing is making the evaluation seriously rather than defaulting to “not yet.” Define your specific pain points, model the ROI for your actual situation, and talk to pathologists in practices similar to yours who have made the transition. That conversation is more useful than any vendor presentation, including ours.
What Digital Pathology Actually Changes for You as a Pathologist
Your Physical Experience of Work
Traditional microscopy is physically demanding in ways that accumulate over a career. Neck strain, back pain, and eye fatigue from hours at the eyepiece are occupational realities for high-volume pathologists. This isn’t trivial, as it affects diagnostic stamina and quality in the back half of a long day.
Digital pathology moves your work to a monitor at eye level, with an ergonomic workstation that you can configure for your posture and your preferences. Navigation is done with a mouse or controller rather than fine motor adjustments to an eyepiece. The repetitive physical strain that comes with microscopy largely disappears.
Lighting is also fully controllable in a digital environment. Screen brightness, contrast, and display settings can be optimized for your visual comfort and adjusted throughout the day. For pathologists who deal with eye fatigue, this is a meaningful quality-of-life improvement.
Where You Can Work
Geographic constraints are the most immediate structural change digital pathology creates. If your slides are digital, you can diagnose from any validated location with a sufficient monitor and internet connection. That means working from home without reduced diagnostic capability. It means covering multiple sites without physically traveling between them. It means getting a second opinion from a specialist at another institution without shipping slides and waiting days.
For many pathologists, particularly those covering large regions or multiple facilities, this is not a minor convenience. It changes the fundamental structure of how their practice operates.
Dr. Liron Pantanowitz uses a unique analogy with skeptical pathologists. He compares the microscope to a landline telephone and digital pathology to a mobile phone. Your landline gives you a crystal-clear connection, but you have to be at your desk to use it. Your mobile phone may occasionally drop a call in a tunnel, but you would never give up its portability to be tied to one location for every conversation. And more importantly, it’s not the call quality that makes your mobile phone indispensable. It’s all the applications that live on it.
“When you explain that to pathologists,” Dr. Pantanowitz shared on the PathPulse podcast, “that one, you gain the portability, yes, at the expense sometimes of having a perfect microscopic image, but it’s all the applications that you will have in the future that you can’t give up now. And so they get that.”
The remote work dimension of digital pathology also has direct implications for recruitment and retention. Many pathologists trained in digital environments now expect that flexibility as a baseline. Practices that can offer remote diagnostic capability have a meaningful advantage in attracting the next generation of pathologists.
The Learning Curve Is Real but Shorter Than You Think
The transition to digital pathology requires learning new tools and new navigation habits. That takes time. Most pathologists describe a period of reduced comfort and slightly slower throughput during the first weeks of use. This is normal and worth acknowledging rather than minimizing.
What the data consistently shows, however, is that the adjustment period is shorter than anticipated. Dr. Todd Randolph, a board-certified pathologist with nearly three decades of experience, adapted to reading digital cases in under five minutes. That’s an outlier, but it illustrates that experienced pathologists often find the transition more manageable than they expected.
NYU Langone’s Dr. Hoda took a deliberate sequencing approach to ease his team through the transition: proficiency in daily digital workflow first, AI integration second, remote sign-out third. Reaching one level of competence before introducing the next reduces cognitive overload and builds genuine confidence rather than surface-level compliance.
AI Becomes Available to You
This deserves careful framing. Digital pathology does not require AI. Andy Ivie, Lumea’s Chief Innovation Officer, wrote a piece specifically addressing the reasons to adopt digital pathology that have nothing to do with AI. It’s worth reading before drawing conclusions about whether AI is relevant to your practice.
That said, digital pathology is the infrastructure that makes AI possible. If you ever want access to tools that assist with cell counting, biomarker quantification, triage, or pre-screening, none of that is available to a microscope. Whether or not you use AI now, staying on a glass slide workflow means those options remain permanently unavailable to you.
Dr. Hoda put it directly: “Adopting a digital workflow means that we’re comfortable with moving into the future. If we’re not adopting it, it means we’re hesitant, and we’re not going to move into AI in the way that it’s going to be meaningful for patients.”
What Digital Pathology Changes for Your Practice
Collaboration Without Logistics
Getting a second opinion on a challenging case currently involves either shipping physical slides or having a colleague come to your microscope. Digital pathology makes consultation instant. You share a case, your colleague views it from wherever they are, and you have a synchronous or asynchronous conversation about it. The barrier to seeking expert input drops dramatically, which benefits both diagnostic quality and professional development.
Consultation and Referral Revenue
For pathology groups offering subspecialty consultation services, digital pathology removes the geographic limit on who you can serve. You can provide expertise to institutions and practices that couldn’t access it before, without the cost and logistical burden of slide shipping. For independent practices and growing groups, this is a meaningful revenue opportunity.
Education and Tumor Boards
Digital pathology transforms tumor board presentations. Rather than describing findings verbally or presenting photomicrographs taken at fixed magnifications, you can navigate a live digital slide in real time, zoom to any region, and show exactly what you’re seeing to the entire room. The same capability applies to resident teaching and case conferences. Educational libraries can be built and maintained without organizing physical slide collections.
Future Compatibility
Regulatory standards, accreditation requirements, and institutional expectations around digital pathology are evolving. Labs that begin the transition now build the infrastructure, the validation record, and the staff expertise that will be required as digital primary diagnosis becomes the standard of care rather than the exception. Labs that delay that work will eventually face a more compressed and more disruptive transition.
Common Concerns, Addressed Directly
“What about the z-axis? I’ll miss tissue thickness.” This is a legitimate technical concern for certain tissue types and applications. Most pathologists transition successfully without it, and for cases where three-dimensional tissue evaluation is genuinely necessary, glass slide review remains available. In practice, the cases where z-axis information is diagnostically critical are a small fraction of a typical surgical pathology volume.
“What if the technology fails?” Technology failures happen. A well-designed digital pathology implementation includes redundancy planning: backup scanners, documented downtime procedures, and contingency workflows that keep patient care moving when a system component is unavailable. The question to ask vendors is not “will it ever fail?” but “what happens when it does?”
“Will my diagnostic accuracy suffer?” The evidence consistently shows diagnostic concordance between digital and glass slide pathology is equivalent, and FDA 510(k) clearance for primary clinical diagnosis requires demonstrating that equivalence. Lumea’s Viewer+ holds that clearance. Additionally, tissue-handling technology that improves specimen quality from the point of collection, reducing fragmentation and preserving anatomic orientation, means the digital image your pathologists are reviewing can be materially better than what glass slide preparation alone provides.
“I’m too busy to go through a transition right now.” This one is understandable, and there’s no perfect time for a major workflow change. What’s worth noting is that the transition is manageable when it’s planned and phased. Labs that have done it successfully started small, one specimen type, one pathologist group, and expanded progressively. The disruption is real but bounded. The disruption of continuing to operate a fully physical workflow as digital pathology becomes the institutional and regulatory expectation will eventually be larger.
What Experienced Pathologists Say After Making the Switch
The most useful perspective isn’t from vendors or administrators. It’s from pathologists who were skeptical, made the transition, and are now practicing digitally.
Dr. Hoda described what the transformation did for pathology’s standing at NYU Langone: more medical students rotating through the department than ever before, equal standing with radiology at tumor boards, and the disappearance of the perception that pathology is a slow-moving specialty. “It takes the lid off the potential cap that was kind of there,” he said. “How would we ever even think about moving towards the future if we don’t take the little cap off and move into that space?”
Dr. Adam Cole, founder of TruCore Pathology, framed it in terms of what matters most: “We’re all doctors. We all got into this field for a reason: the patient is central to everything we do. Using Lumea technology simply results in a better end product for our patients.”
Dr. Pantanowitz offered perhaps the most direct closing message for pathologists still on the fence. Medicine has always required adaptation, he argues, and digital pathology is simply the current form of that adaptation. “It’s not the most intelligent of the species, or the strongest or the toughest,” he said, echoing Darwin. “It’s the one that’s going to be willing to adapt and change and undergo evolution. That’s the species that will survive. So you can be the pathologist that thinks you’re smart enough that you don’t need it, or you can be willing to adapt and undergo some evolution, and you’ll be the pathologist that will most likely be able to survive in the future.”
These aren’t testimonials from early adopters who were looking for an adventure. They’re from practicing pathologists who approached the transition with the same scrutiny they apply to diagnostic questions, and concluded it was worth it.
A Practical Starting Point
If you’re considering the transition, the most useful first step is not evaluating scanners or software. It’s defining what problem you’re trying to solve. The pathologists who get the most from digital pathology are those who went in with a specific goal: reducing turnaround time, enabling remote work, gaining access to AI tools for a particular application, or scaling capacity across multiple sites.
With a defined goal, vendor evaluation becomes straightforward, ROI becomes measurable, and the transition has a clear rationale that you can communicate to your team. Ready to start the conversation? Request more information from us today. Or visit our solutions page for pathology or our guide to implementing digital pathology to learn more.
